199P Impact of Baseline Tumour Burden on Outcomes in EMERALD-1: A Phase III Study of Durvalumab (D) ± Bevacizumab (B) with Transarterial Chemoembolisation (TACE) in Embolisation-Eligible Unresectable Hepatocellular Carcinoma (Uhcc)
Annals of Oncology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要